Saudi Arabia's pharmaceutical market generated approximately $11.8 billion in revenue in 2024 and is projected to reach $15.6 billion by 2030, growing at a CAGR of 4.7%. This expansion is being driven by rising healthcare expenditure, Vision 2030 reforms, and growing demand for advanced therapeutics, biologics, and specialty drugs — reinforced by improved access to healthcare facilities and expanding insurance coverage. Biologics and biosimilars represent the fastest-growing segment, while Saudi Arabia is projected to lead the Middle East and Africa regional market in revenue by 2030.
Raising the standard for excellence in care.
Raising the standard for excellence in care.